myAIHAteam

That's a great question to bring to the community! Brukinsa (zanubrutinib) belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors. These work by interrupting immune signals that drive red blood cell destruction in warm AIHA.

BTK inhibitors like zanubrutinib are currently being studied as an Show Full Answer

That's a great question to bring to the community! Brukinsa (zanubrutinib) belongs to a class of drugs called Bruton's tyrosine kinase (BTK) inhibitors. These work by interrupting immune signals that drive red blood cell destruction in warm AIHA.

BTK inhibitors like zanubrutinib are currently being studied as an investigational approach for warm AIHA, particularly for cases that are difficult to treat or keep coming back. While no myAIHAteam members have shared experiences with Brukinsa specifically in the available community discussions, it's worth knowing that the warm AIHA treatment landscape is evolving. Here's a quick snapshot of where BTK inhibitors fit in:

- First-line: Corticosteroids (e.g., prednisone) remain the standard starting point
- Second-line: Rituximab is commonly used when steroids aren't enough
- Emerging options: BTK inhibitors like zanubrutinib and rilzabrutinib are being researched for harder-to-treat cases
- Newest approval: Nipocalimab-aahu (Imaavy) was FDA-approved in August 2026 for warm AIHA in people 12+ who have used corticosteroids

Since zanubrutinib is still investigational for warm AIHA, it's really important to have a detailed conversation with your care team about potential benefits and risks before starting. Keeping a symptom and side effect log can also help track how any new treatment is working for you.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Treatment Options for Warm AIHA

Warm Autoimmune Hemolytic Anemia: Symptoms, Treatment, and More